Macquarie Group Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 758,697 shares of the company’s stock after selling 17,193 shares during the quarter. Macquarie Group Ltd. owned approximately 0.86% of Neurocrine Biosciences worth $34,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC boosted its position in shares of Neurocrine Biosciences by 9.8% during the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after acquiring an additional 1,180,874 shares during the last quarter. Vanguard Group Inc. raised its stake in Neurocrine Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after purchasing an additional 186,329 shares in the last quarter. BlackRock Inc. raised its stake in Neurocrine Biosciences by 14,216.0% during the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after purchasing an additional 4,996,784 shares in the last quarter. Janus Capital Management LLC raised its stake in Neurocrine Biosciences by 85.0% during the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after purchasing an additional 2,002,899 shares in the last quarter. Finally, BB Biotech AG raised its stake in Neurocrine Biosciences by 7.7% during the second quarter. BB Biotech AG now owns 3,446,552 shares of the company’s stock valued at $158,541,000 after purchasing an additional 245,000 shares in the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Finally, Robert W. Baird reiterated an “outperform” rating and set a $66.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and a consensus price target of $68.81.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down 1.08% during mid-day trading on Wednesday, hitting $60.21. The company’s stock had a trading volume of 101,904 shares. The firm has a 50 day moving average of $58.73 and a 200-day moving average of $51.36. The firm’s market cap is $5.31 billion. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $63.77.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The firm had revenue of $6.34 million for the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter in the prior year, the company earned ($0.46) EPS. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current fiscal year.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 26,250 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the sale, the insider now directly owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares of the company’s stock, valued at $3,412,013.92. The disclosure for this sale can be found here. Insiders sold a total of 132,580 shares of company stock worth $7,440,850 in the last 90 days. 4.80% of the stock is currently owned by company insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.